AU2002220702A1 - Quinoline derivatives as nk-3 and nk-2 antagonists - Google Patents
Quinoline derivatives as nk-3 and nk-2 antagonistsInfo
- Publication number
- AU2002220702A1 AU2002220702A1 AU2002220702A AU2070202A AU2002220702A1 AU 2002220702 A1 AU2002220702 A1 AU 2002220702A1 AU 2002220702 A AU2002220702 A AU 2002220702A AU 2070202 A AU2070202 A AU 2070202A AU 2002220702 A1 AU2002220702 A1 AU 2002220702A1
- Authority
- AU
- Australia
- Prior art keywords
- antagonists
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000005557 antagonist Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0027696A GB0027696D0 (en) | 2000-11-13 | 2000-11-13 | Novel compounds |
| GB0027696 | 2000-11-13 | ||
| GB0109119A GB0109119D0 (en) | 2000-11-13 | 2001-04-11 | Novel compounds |
| GB0109119 | 2001-04-11 | ||
| PCT/EP2001/013139 WO2002038547A1 (en) | 2000-11-13 | 2001-11-12 | Quinoline derivatives as nk-3 and nk-2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002220702A1 true AU2002220702A1 (en) | 2002-05-21 |
Family
ID=26245280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002220702A Abandoned AU2002220702A1 (en) | 2000-11-13 | 2001-11-12 | Quinoline derivatives as nk-3 and nk-2 antagonists |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040082589A1 (en) |
| EP (1) | EP1334089A1 (en) |
| JP (1) | JP2004517062A (en) |
| AU (1) | AU2002220702A1 (en) |
| WO (1) | WO2002038547A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| EP1541149A1 (en) * | 2002-06-26 | 2005-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| WO2005000247A2 (en) * | 2003-06-25 | 2005-01-06 | Smithkline Beecham Corporation | 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
| BRPI0510365A (en) | 2004-04-28 | 2007-11-06 | Takeda Pharmaceutical | compound, method of producing a compound, nk2 receptor antagonist, prodrug, pharmaceutical agent, methods for antagonizing an nk2 receptor and preventing or treating functional gastrointestinal disorders, and use of the compound or a prodrug thereof |
| GB0428327D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Ab | Method |
| EP1831164A1 (en) * | 2004-12-24 | 2007-09-12 | AstraZeneca AB | Heterocyclic compounds as ccr2b antagonists |
| GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0525957D0 (en) * | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| PE20091093A1 (en) | 2007-12-03 | 2009-08-25 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND CONTAINING NITROGEN AND ITS USE |
| USRE49686E1 (en) | 2008-09-19 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR004735A1 (en) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. |
| BR9809652A (en) * | 1997-05-23 | 2001-09-11 | Smithkline Beecham Spa | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
| AU768708B2 (en) * | 1998-11-20 | 2004-01-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
-
2001
- 2001-11-12 JP JP2002541083A patent/JP2004517062A/en active Pending
- 2001-11-12 WO PCT/EP2001/013139 patent/WO2002038547A1/en not_active Ceased
- 2001-11-12 EP EP01993602A patent/EP1334089A1/en not_active Withdrawn
- 2001-11-12 AU AU2002220702A patent/AU2002220702A1/en not_active Abandoned
- 2001-11-12 US US10/416,596 patent/US20040082589A1/en not_active Abandoned
-
2006
- 2006-06-26 US US11/426,414 patent/US20070015766A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070015766A1 (en) | 2007-01-18 |
| EP1334089A1 (en) | 2003-08-13 |
| JP2004517062A (en) | 2004-06-10 |
| US20040082589A1 (en) | 2004-04-29 |
| WO2002038547A1 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1047402A (en) | Quinoline and quinazoline derivatives | |
| IL154618A0 (en) | Quinolinone derivatives | |
| IL159288A0 (en) | Tetrahydroquinoline derivatives | |
| PL347721A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| IL173036A0 (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| IL160750A0 (en) | Quinoline derivatives as neuropeptide y antagonists | |
| ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
| HRP20041031A2 (en) | Quinolinone derivatives | |
| PL372295A1 (en) | Quinoline derivatives as npy antagonists | |
| MXPA02008402A (en) | Derivatives of quinoline as alpha-2 antagonists. | |
| EP1408971A4 (en) | Novel quinolines and uses thereof | |
| IL133036A0 (en) | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists | |
| AU2002347336A1 (en) | Quinoline derivatives | |
| AU2002215043A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | |
| AU2002220702A1 (en) | Quinoline derivatives as nk-3 and nk-2 antagonists | |
| AU2002226356A1 (en) | Quinoline derivatives as nk-3 antagonists | |
| GB0104422D0 (en) | Quinoline derivative | |
| PL377318A1 (en) | Tetrahydroquinoline derivatives | |
| AU2002347359A1 (en) | Quinoline derivatives | |
| EG24415A (en) | Quinoline derivatives | |
| WO2002047456A3 (en) | Urotensin-ii receptor antagonists | |
| AU2002365664A1 (en) | Quinoline derivatives as antitumour agents | |
| AU2002302735A1 (en) | 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists | |
| AU2002216939A1 (en) | Quinoline derivatives and their use as anti-epileptics | |
| AU2002310838A1 (en) | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |